Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · July 18, 2023

Safety and Clinical Activity of Autologous RNA CAR T-Cell Therapy in Patients With Myasthenia Gravis

The Lancet Neurology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Neurology
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study
Lancet Neurol 2023 Jul 01;22(7)578-590, V Granit, M Benatar, M Kurtoglu, MD Miljković, N Chahin, G Sahagian, MH Feinberg, A Slansky, T Vu, CM Jewell, MS Singer, MV Kalayoglu, JF Howard, T Mozaffar

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading